Trust Size
$1M
Peak Price
$8750.00
Current Price
$0.27
Return
-97.3%
Price Journey
What Happened
ZyVersa Therapeutics is a clinical-stage biopharmaceutical company developing therapies targeting inflammasomes and extracellular vesicles for kidney disease and inflammatory conditions.
ZyVersa Therapeutics went public through a SPAC merger and trades under ZVSA. The company is advancing IC 100, an anti-inflammasome therapy, and VAR 200, a cholesterol efflux mediator, for chronic kidney disease and related inflammatory conditions. The stock has declined sharply with a reverse stock split executed.
Timeline
2021-12-07
S-1 Registration Filed
🔀 Reverse Stock Split
Reverse split ratio: . Reverse splits are used to avoid delisting but destroy shareholder value through the illusion of a higher stock price.
SEC Filing Details
CIK Number
1859007
Total SEC Filings
314
State of Incorporation
DE
Last Filing Date
2026-03-05
Business Location
Somerville, NJ
Trust/Asset Size
$1M
Data sourced from SEC EDGAR Company Facts API and EFTS search index.
📄 SEC Filings
View all EDGAR filings for ZyVersa Therapeutics